中剂量阿糖胞苷加米托蒽醌对老年原发性急性髓性白血病缓解后治疗与低剂量阿糖胞苷一样有效，但毒性更大

{"title":"中剂量阿糖胞苷加米托蒽醌对老年原发性急性髓性白血病缓解后治疗与低剂量阿糖胞苷一样有效，但毒性更大","authors":"Matt Kalaycio MD","doi":"10.1054/ebon.2002.0019","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":100515,"journal":{"name":"Evidence-based Oncology","volume":"3 2","pages":"Pages 74-76"},"PeriodicalIF":0.0000,"publicationDate":"2002-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1054/ebon.2002.0019","citationCount":"0","resultStr":"{\"title\":\"Intermediate dose cytarabine plus mitoxantrone is as effective as, but more toxic than, low-dose cytarabine for postremission therapy among older patients with primary acute myeloid leukemia\",\"authors\":\"Matt Kalaycio MD\",\"doi\":\"10.1054/ebon.2002.0019\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":100515,\"journal\":{\"name\":\"Evidence-based Oncology\",\"volume\":\"3 2\",\"pages\":\"Pages 74-76\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2002-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1054/ebon.2002.0019\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Evidence-based Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S136340540290019X\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Evidence-based Oncology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S136340540290019X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}